CD69 and acute myeloid leukemia: The activity of CC-96191 against the AML cells correlated with an increase in bone marrow NK cell activation, as determined by increased numbers of NK cells expressing CD69, with CC-96191 being more potent than lintuzumab in inducing NK cell activation and achieving a higher maximal number of cells activated (Figure 6C).